Skip to main content

Advertisement

SpringerLink
Log in

When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?

  • Clinical Trials Report
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  2. Rosen CJ: The rosiglitazone story-lessons from an FDA advisory committee meeting. N Engl J Med 2007, 357:844–846.

    Article  PubMed  CAS  Google Scholar 

  3. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189–1195.

    Article  PubMed  CAS  Google Scholar 

  4. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  5. Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578–581.

    PubMed  Google Scholar 

  6. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.

    Article  PubMed  CAS  Google Scholar 

  7. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256–263.

    Article  PubMed  CAS  Google Scholar 

  8. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  9. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.

    Article  PubMed  CAS  Google Scholar 

  10. Karalliedde J, Buckingham R, Starkie M, et al.: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. 2006, J Am Soc Nephrol 17:3482–3490.

    Article  PubMed  CAS  Google Scholar 

  11. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–2559.

    Article  Google Scholar 

  12. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Article  Google Scholar 

  13. BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503–2515.

    Article  Google Scholar 

  14. Retnakaran R, Zinman B: Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet 2009, 373:2088–2090.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes and Hormone Center of Excellence, University of Virginia Health System, Box 801407, 450 Ray C. Hunt Drive, Charlottesville, VA, 22908, USA

    Anthony L. McCall

Authors
  1. Anthony L. McCall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony L. McCall.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCall, A.L. When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?. Curr Diab Rep 9, 325–328 (2009). https://doi.org/10.1007/s11892-009-0063-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-009-0063-0

Keywords

Search

Navigation